Celldex Therapeutics (CLDX) to Release Quarterly Earnings on Thursday

Key Points

• Celldex Therapeutics is set to announce its Q2 2025 earnings on August 14, with expectations of a loss of ($0.86) per share and revenue of $1.13 million.
• In the previous quarter, Celldex's earnings were ($0.81) per share, missing estimates, with a negative return on equity of 23.46%.
• Analysts hold a consensus rating of “Moderate Buy” on CLDX, with an average price target of $50.11, despite recent downgrades from firms like Goldman Sachs and UBS.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 7th. Analysts expect Celldex Therapeutics to post earnings of ($0.86) per share and revenue of $1.13 million for the quarter.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.01. Celldex Therapeutics had a negative return on equity of 26.78% and a negative net margin of 3,446.88%. The business had revenue of $0.73 million during the quarter, compared to analysts' expectations of $1.13 million. On average, analysts expect Celldex Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Celldex Therapeutics Trading Down 2.6%

CLDX stock traded down $0.55 during trading hours on Friday, hitting $20.66. 770,909 shares of the stock traded hands, compared to its average volume of 870,012. The stock has a 50-day simple moving average of $21.54 and a 200 day simple moving average of $20.72. Celldex Therapeutics has a one year low of $14.40 and a one year high of $47.00. The company has a market cap of $1.37 billion, a P/E ratio of -6.86 and a beta of 1.22.

Hedge Funds Weigh In On Celldex Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Celldex Therapeutics by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company's stock worth $798,000 after acquiring an additional 680 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Celldex Therapeutics by 12.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company's stock worth $2,383,000 after acquiring an additional 14,979 shares during the period. Finally, Millennium Management LLC boosted its position in Celldex Therapeutics by 327.3% during the 1st quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company's stock worth $7,259,000 after acquiring an additional 306,330 shares during the period.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. HC Wainwright reaffirmed a "buy" rating and set a $50.00 target price on shares of Celldex Therapeutics in a research note on Friday, June 13th. The Goldman Sachs Group decreased their target price on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. UBS Group decreased their target price on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Morgan Stanley decreased their target price on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. Finally, Canaccord Genuity Group started coverage on Celldex Therapeutics in a research note on Monday, April 28th. They set a "buy" rating and a $64.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Celldex Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $50.11.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.